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journal homepage: www.elsevier .com/locate /rmedLETTER TO THE EDITOROn the need for competent evaluation of trial qualityEditor: Oba, Thameem, and Zaza1 concluded, on the basis
of five published trials, that higher levels of PEEP could
result in less respiratory distress. The authors’ misgivings
regarding pooling the studies were not based on trial
quality heterogeneity, but one does not mix pure and
contaminated water, so given the existence of one trial2
rated as perfect 5/5 on the Jadad score, it is unclear
what is added by studies rated as 3 or lower. Low study
quality invites bias, which persists even with pooling and
larger sample sizes. Hence, we would opt to skim off the
top study and leave it at that. But given the gross inad-
equacies of the Jadad score as a measure of trial quality,3
even a perfect 5/5 cannot guarantee even the lowest
level of trial quality,4 so we took a closer look. In fact
there were egregious errors in this trial, and that these
errors were given a free pass by the authors who were
cavalier enough to use the Jadad score in lieu of any
serious scrutiny of trial quality, but even if we limit
ourselves to the unjustifiably limited set of measures
considered by the Jadad score, we still come up short.
A trial rated as 5 needs to be properly randomized and
properly masked. This trial was neither. Masking was
addressed only as far as noting the data analysis to be
masked, so we have to assume that this was an unmasked
trial, and points need to be deducted, although the lack of
an explicit statement one way or another is itself a flaw in
the study. In an unmasked trial, allocation concealment is
impossible if the randomization is conducted with any
restrictions.5 While some restrictions may still be appro-
priate anyway, under no circumstances is it ever justifiable
to use a procedure as restrictive as permuted blocks in an
unmasked trial,5 and yet this exactly what Meade et al.2
did. The combination of an open label design and
permuted blocks precludes the very possibility of alloca-
tion concealment, and makes selection bias a real issue.
How, then, can the trial get full credit for this dimension
of the Jadad score? There is a serious issue even without
observable baseline imbalances, because there can always
be unobserved baseline imbalances. But in this case,
there are also several noteworthy baseline imbalances in
Table 3. These were dismissed with a highly inappropriate
application of the Bonferroni correction, which served to0954-6111/$ - see front matter ª 2012 Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.rmed.2012.07.015reduce the nominal alpha level (presumably 0.05) to one
25th of that (which would be 0.002), for baseline
comparisons only. This would constitute research
malpractice even if there truly were 25 (or 27, as we
counted) independent baseline variables. But there
aren’t; 12 of these are causes of lung injury, which were
artificially itemized to increase the number of variables
and decrease the alpha level, possibly to just below the
lowest p-value (which was not reported, so we cannot
know).
An additional error led to unplanned unequal allocation,
which was addressed with some black box sensitivity anal-
yses with little elaboration, so the reassurances are not
compelling. Beyond randomization errors, there is also the
exclusion of randomized patients from analyses the authors
misrepresented as “intent to treat”. We wonder how so
flawed a trial can make it through both internal institu-
tional scrutiny and peer review, and then receive that
perfect 5/5. The bottom line is that your readers have been
misled, because if these five trials are the best, or only
trials that suggest that higher levels of PEEP could result in
less respiratory distress, then we really have no idea if this
is true or not.
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